AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
908 Devices Inc.
Video analysis: MASS
All videosNo video analysis for this stock yet. Request one from our team.
News: MASS
Comparing 908 Devices (NASDAQ:MASS) & Plexus (NASDAQ:PLXS)
Plexus (NASDAQ: PLXS - Get Free Report) and 908 Devices (NASDAQ: MASS - Get Free Report) are both technology companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings. Analyst Ratings This is a breakdown of current ratings
BlackRock Inc. Takes $16.91 Million Position in 908 Devices Inc. $MASS
BlackRock Inc. acquired a new stake in shares of 908 Devices Inc. (NASDAQ: MASS) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,944,236 shares of the company's stock, valued at approximately $16,915,000. BlackRock Inc. owned approximately 5.14% of
908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City.908 Devices' management is scheduled to present at 3:45 p.m. Eastern Time. The presentation is webcast and interested parties can register for th.
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices (NASDAQ: MASS) outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue. Speaking at the Midwest IDEAS Conference, CEO and Co-Founder Kevin Knopp said the company has spent the past 18 months reshaping its operations around portable tools
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices NASDAQ: MASS outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue.
Is 908 Devices Inc (MASS) Overvalued After 3.3% Rally? GF Value Says Overvalued
On August 21, 2026, 908 Devices Inc (MASS) shares rose 3.3% to $10.68, marking a notable increase within its 52-week range of $5.03 to $10.70. The stock has sho
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market
908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.
